In this line, a recent retrospective cross-sectional multicenter study in neuromyelitis optica spectrum disorder (NMOSD)/myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) patients treated with anti-IL-6 receptor therapy found a 100% seroconversion rate after a COVID-19 vaccination, despite titers being lower than in healthy controls, although comparable to csDMARDs and higher than B-cell depleting agents [61]. This evidence concerns the gene MOG and COVID-19.